规范ARB治疗从共识到临床的应用.pptVIP

INNOVATION recruited 527 patients with type 2 diabetes and evidence of incipient nephropathy.1,2 Hypertension was not an inclusion criterion. Makino H, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; in press. Makino H, et al. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy – rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker telmisartan, investigation on type 2 diabetic nephropathy (INNOVAT